It is estimated there are 350-400 million people worldwide chronically infected with HBV. Many of these are women and of reproductive age. As such, they may face therapeutic decisions regarding antiviral therapy and the implication this may have on future or current pregnancies. This article reviews the data of all antivirals licensed for use against hepatitis B infection regarding teratogenicity, carcinogenicity, clinical experience during pregnancy, placental transfer and excretion in breast milk.
It is estimated there are approximately 350-400 million individuals chronically infected with HBV worldwide [1] . Exposure to HBV early in life is associated with the highest rates of chronic infection, with 90% of children developing chronic infection if infected in the first year of life with subsequent rates progressively decreasing with increasing age at the time of exposure [2, 3] . Women from countries endemic for HBV who are infected at a young age, often remain chronically infected with HBV during their reproductive years and are an important source for ongoing perinatal transmission. As a result it is common for these women to face therapeutic decisions regarding HBV infection during this time.
The number of treatment options available for HBV has increased in the last decade and now include interferon-α (both standard and pegylated), lamivudine, entecavir, tenofovir, adefovir and telbivudine. All large registration trials of these agents have specifically excluded pregnant or breastfeeding women. Consequently they have not been licensed for use in this population. Moreover there have been no prospective studies in pregnant women directly comparing the safety and efficacy of specific antiviral agents. This has resulted in a marked lack of experience of antiviral agents in this group of patients. Despite this, women of reproductive age with chronic HBV infection often require treatment of their HBV infection; therefore, this indication needs to be balanced against their reproductive intent. Furthermore women already on therapy may become pregnant, raising issues of safety to the fetus. In addition to maternal indications for therapy, there is also increasing data which suggests that antiviral therapy may be of benefit over and above hepatitis B vaccination and hepatitis B immunoglobulin in preventing mother-to-child transmission [4] . If these medications are used in this patient population, the important considerations include: whether the drug crosses the placenta, whether the drug is teratogenic, and whether the drug is excreted in breast milk and can harm the infant.
The safety of drugs in pregnancy is stratified by the FDA into a classification system on the basis of experience of human exposure and the potential to cause harm to the fetus from animal studies. The other major source of information on teratogenicity is derived from the Antiretroviral Pregnancy Registry, which was initially established in 1989 to evaluate teratogenicity of HIV agents. Since 2003 this has also included antivirals with activity against HBV. The registry is voluntary and collects information on congenital anomalies in exposed offspring and compares the rate of congenital anomalies with the background rate from sentinel counties in Atlanta (GA, USA). While this resource deals with the issue of teratogenicity, it does not address the issue of Introduction toxicity in exposed infants either during the third trimester or post-partum during breastfeeding when teratogenicity is no longer relevant but toxicity may occur.
The purpose of this review is to summarize the data currently available for antiviral agents licensed for use in chronic HBV infection with a particular focus on their known effect on reproduction, pregnancy and breastfeeding. Each medication is discussed in detail with a summary provided in Table 1 .
Interferon-α
Interferon-α is a class of immune modulating agents that has been licensed for the treatment of chronic HBV since 1992. Interferons possess in vitro antiviral, immunomodulatory and anti-proliferative activity and work by binding to specific receptors on the cell surface thereby initiating intracellular signalling and activation of gene transcription. The products resulting from gene transcription act to inhibit viral replication within cells and cell proliferation [5] . Accordingly, they are used in the treatment of viral infections and malignancies.
Standard interferons have previously been demonstrated to achieve approximately 30% hepatitis B e antigen (HBeAg) seroconversion [6] . More recently, interferon-α has been modified by conjugation with a polyethylene glycol side chain. This alters its pharmacology to allow weekly administration and is now the preferred form of interferon for treatment of HBV, and results in similar rates of HBeAg seroconversion [7, 8] which are largely sustainable [9] . Given that there is a defined duration of therapy with interferons, they are particularly suited to the treatment of female patients of reproductive age in an attempt to avoid long-term nucleoside/nucleotide analogue therapy. However, the significance of HBV DNA rebound after ceasing interferon therapy in this group of patients is unknown.
Data on the pharmacokinetics of interferons in pregnancy are limited. A study of two women given a single intramuscular dose prior to termination of pregnancy [10] reported that interferon was undetectable in fetal blood and amniotic fluid. Animal studies have reported a similar finding with no placental transfer demonstrated unless the interferon was coadministered with a chemical inducer [11] .
Another study attempted to measure placental transfer as well as excretion of interferon in human breast milk in two women. The authors measured neonatal serum levels as a surrogate marker of placental transfer along with a sample of breast milk and correlated it to maternal serum levels in two women with chronic myeloid leukaemia treated with interferon-α (8 million units daily and 8 million units three times per week, respectively) during pregnancy [12] . A blood sample from the first newborn was tested for the level of interferon and was found to be <0.6 U/ml compared with 20.8 U/ml in the maternal serum, whereas the concentration in breast milk was 1.4 U/ml. In the second newborn, immediate post-partum levels were <1 U/ml in the newborn and 58 U/ml in the mother, and levels in breast milk were 6 U/ml [12] . The conclusion from the authors of this paper was that there was minimal placental transfer due to the large size of the molecule. Another case report measured breast milk interferon concentration on two occasions prior to a large intravenous dose of interferon for malignant melanoma, and then on five occasions post-dose over the next 21 h [13] . The authors found that even after massive doses of drug (30 million IU), interferon levels in breast milk were only marginally increased above control samples. They concluded that even after very large doses, interferon is not excreted in human breast milk at levels high enough to be clinically relevant or to induce side effects in the breastfed infant. This was thought to be due to the mammary alveolar epithelial cell barrier, which is impervious to substances with a molecular weight >1,000 daltons, particularly after the first 2 weeks post-partum [13] .
There are no reported animal studies examining the potential teratogenicity of interferon in animal models. Despite the recommendation to avoid interferon during pregnancy, it has been used by pregnant women for a variety of medical conditions including chronic myelogenous leukaemia [14] , essential thrombocythaemia [15] and chronic inflammatory demyelinating polyneuropathy (CIDP) [16] . There are also case reports of fetal exposure following unplanned pregnancy during its administration for conditions such as hepatitis C infection [17] . In the case of CIDP, treatment has been used for the entire duration of a successful pregnancy, although the fetus was delivered at 33 weeks secondary to the development of maternal pre-eclampsia. It is difficult to ascertain if the associated intrauterine growth restriction was related to the antiproliferative effect of interferon or the pre-eclampsia [16] . A series of 26 pregnancies with interferon exposure reported no abortions or fetal malformations in 27 cases where interferon was used alone [18] . A higher incidence of intrauterine growth restriction among infants exposed compared with the general population has been documented [19] , although a causal effect has not been established due to small numbers (6/27, 22%). More recently, there has been a case report of an infant exposed to pegylated interferon for 16 weeks in utero with no evidence of fetal malformation [19] .
There have been no clinical studies of interferons in pregnancy; therefore, the safety in this setting has not been established, This, together with its very limited data in animal studies, means that its use is not advised, especially given its known antiproliferative effects. 
Lamivudine
Lamivudine is a member of the nucleoside reverse transcriptase inhibitor class of antiretroviral drugs. It is a dideoxynucleoside analogue of cytidine and is a potent inhibitor of HIV-1 and HIV-2, as well as HBV [20] . Lamivudine was the first oral agent to show efficacy against and to be licensed for the treatment of HBV. Studies in non-pregnant chronic HBV infection have demonstrated that lamivudine therapy for 52 weeks leads to improved hepatic necroinflammatory scores and reduces progression of fibrosis. In addition, HBeAg seroconversion, suppression of HBV DNA replication and normalization of alanine aminotransferase (ALT) levels was observed in 16%, 98% and 72% of individuals, respectively [21] . A further placebo-controlled, randomized, double-blind clinical trial of lamivudine in chronic HBV infection and advanced liver disease also demonstrated its efficacy in decreasing liver disease progression, and reduced the rates of hepatocellular carcinoma and hepatic decompensation [22] . Unfortunately this drug has been associated with high levels of HBV resistance when used long term [23] , and with the advent of newer agents with higher barriers to resistance, its routine use in clinical practice has become more limited. In pregnant women, lamivudine crosses the placenta readily by simple diffusion [24] . In a study of 57 HIVinfected pregnant women receiving lamivudine as part of their antiretroviral therapy, maternal blood, cord blood and amniotic fluid samples correlated with fetal concentrations [25] . Indeed, the median concentration in the amniotic fluid was 5× higher than that in maternal plasma [25] . Animal teratogenicity studies have been performed in rats and rabbits with exposures up to 40 and 36× higher than human doses, respectively, with no observed teratogenicity [26] . There was, however, a reduction in litter size of rabbits observed at exposures less than that observed at human clinical dosage [26] .
Lamivudine has been used extensively by pregnant women (predominantly for HIV infection), and to date there has been no increase in fetal malformations compared with the background rate as reported to the Antiretroviral Pregnancy Registry for 3,754 first trimester exposures and 6,080 second/third trimester exposures [27] .
Lamivudine is the only HBV antiviral to date that has been used in a randomized controlled trial of pregnant women, where it was studied to determine if it could prevent perinatal HBV transmission [4] . This followed several small observational cohort studies involving women with high viral loads [28] [29] [30] , where it was suggested that it could prevent perinatal transmission when compared rates with historical controls. The more recent study of 114 women was conducted in China and the Philippines [4] . While the intention to treat analysis of the study suggested a significant reduction in HBV transmission to infants whose mothers received lamivudine (10/56 [18%] lamivudine versus 23/59 [39%] placebo; P=0.014), there was a very high loss to follow-up rate in the placebo arm, leading to potentially significant bias. Attempts to adjust for this by sensitivity analyses resulted in a loss of statistical significance [4] .
Lamivudine is found in higher concentrations in human breast milk than serum [31] . The actual concentration, coupled with the average feed volume ingested by an infant suggests the amount of drug the infant would be exposed to via this route is negligible compared with standard oral dosing [32] . In a recent study the median breast milk concentration of lamivudine in 67 HIV-infected women treated with a combination of lamivudine, zidovudine and nevirapine was 1,214 ng/ml compared with 508 ng/ml in maternal plasma (breast milk to plasma ratio 2.56) [33] .
The other issue that has been investigated is that of potential long-term carcinogencity in children exposed to nucleoside analogues in utero or post-partum. A nationwide prospective cohort reported cancer incidence in 8,853 children (median age 5.4 years) exposed to ≥1 antiretroviral drug (5,908 received lamivudine) during pregnancy or post-partum [34] . The incidence did not differ significantly from the general population, with 10 tumours detected. Prematurity and exposure to the combination of didanosine/lamivudine remained independently associated with cancer on multivariate analysis [34] , but the authors advise that longer surveillance is warranted.
Of all the antivirals with activity against HBV, lamivudine has the most safety data in pregnancy and its use in women of reproductive age who are pregnant or considering pregnancy can therefore be recommended if indicated after careful assessment of risk and benefits.
Adefovir dipivoxil
Adefovir dipivoxil is a prodrug of adefovir which, following absorption, is phosphorylated to the active metabolite, adefovir diphosphate, by cellular kinases. Adefovir diphosphate competes with the natural substrate deoxyadenosine triphosphate and is incorporated into viral DNA leading to chain termination. Randomized controlled trials of adefovir in both HBeAgpositive and HBeAg-negative patients have shown it to be superior to placebo at 48 weeks in terms of histological response, HBV DNA level, and HBeAg loss and seroconversion [35, 36] . In addition, in patients with lamivudine-resistant HBV, adefovir in combination with lamivudine is associated with greater reduction in serum HBV DNA and normalization of ALT compared with lamivudine alone [37] . There are no studies of adefovir in pregnant women and no data regarding effect on mother-to-child transmission of HBV. There is no data on placental transfer.
No increase in tumour incidence was reported in carcinogenicity studies in mice and rats at 10 and 4× human doses, respectively [38] . At levels ≥38× higher than human exposure doses, adefovir given intravenously to pregnant rats was associated with increased fetal malformations (anasarca, depressed eye bulge, umbilical hernia and kinked tail) [38] . There have been 39 reports to the Antiretroviral Pregnancy Registry [27] of first trimester adefovir exposure with no reported congenital malformations.
It is not known whether adefovir is excreted in human or animal milk. There have been no clinical studies in pregnancy and given the limited information available its safety in this setting has not been established and its use is not advised.
Entecavir
Entecavir monohydrate is a guanosine nucleoside analogue with activity against HBV polymerase. It is phosphorylated to the active triphosphate form by cellular kinases and then competes with the natural substrate deoxyguanosine-TP and inhibits all three functional activities of HBV polymerase.
Randomized clinical trials using entecavir have demonstrated its superiority to lamivudine in HBV DNA reduction and histological improvement at 48 weeks in both HBeAg-positive and -negative antiviral-naive patients [39, 40] . Sustained virological suppression has been reported after 5 years of therapy with minimal resistance [41] .
There are no clinical studies of entecavir use in pregnant women and no data regarding effect on mother-to-child transmission of HBV.
There is no data regarding placental transfer of entecavir. Entecavir was not genotoxic in in vitro studies, but was carcinogenic in both mice and rats. An increase in the incidence of lung tumours were observed in mice at exposures >3 and 40× that in humans. A number of other tumours were observed at exposures >20× the exposure in humans at 1 mg/day. These tumours tended to appear late after long-term exposure [42] . In rat and rabbit animal models embryofetal development was not affected at exposures up to 28× and 212× human exposure, respectively [42] . At a maternotoxic dose (>2,500× human levels) embryofetal development in the rat was severely retarded. In addition, skeletal malformations in rabbits was observed at drug exposures >883× human levels in the absence of maternal toxicity, and in rats at exposures >3,100× human levels [42] .
Overall 22 prospective cases of entecavir exposure during pregnancy, including follow-up data, have been reported to the Antiretroviral Pregnancy Registry [27] as of 31 July 2010. Further cases of entecavir exposure are required before there would be sufficient numbers to detect an increase in fetal malformations compared with the background rate in the population.
Entecavir monohydrate and/or its conjugate metabolites are excreted in the milk of rats, but it is not known whether human breast milk excretion occurs.
Entecavir has not been studied in pregnant women and, due to its significant carcinogenic potential in animal studies, its use in this population can not be recommended at this time.
Tenofovir
Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester analogue of adenosine monophosphate. It is the prodrug of tenofovir, a nucleotide analogue and obligate chain terminator with activity against HIV reverse transcriptase and HBV polymerase [43] .
In a non-pregnant population, tenofovir was demonstrated to be superior to adefovir through to 48 weeks in a double blind Phase III study, where it demonstrated superior HBV DNA reductions [44] . Tenofovir also has been demonstrated to have a very high barrier to resistance with no reported signature resistance mutations to date. As such, together with entecavir, it has become the preferred oral agent for HBV therapy.
Studies of placental transfer of tenofovir have been performed in HIV-infected women rather than HBVmonoinfected women, and therefore usually in association with other antiretroviral drugs. These studies have reported a median ratio of maternal to umbilical cord concentration of 1.00 [45, 46] . While studies have reported a reduced area under the curve during pregnancy compared with post-partum, no dosage modification during pregnancy is currently recommended [46] . Reproductive toxicity studies in rats and rabbits did not reveal harmful effects to the fetus at concentrations of 4-13 and 66× higher than human exposure levels, respectively. In addition, fertility and embryonic development were not affected in rats by tenofovir exposure at 5× the human therapeutic dose [43] In gravid rhesus monkeys (n=4) administered tenofovir subcutaneously once daily from 20 to 150 days of gestation, there was normal fetal development, although overall body weights and crown-rump lengths were less than those for age-matched controls along with a small reduction in fetal bone porosity [47] . Tenofovir has been taken by pregnant women (predominantly for HIV infection) and to date there has been no increase in congenital malformations compared with the background rate as reported to the Antiretroviral Pregnancy Registry for 981 first trimester exposures and 584 second/third trimester exposures [27] .
Secretion in breast milk has been demonstrated when tenofovir has been administered to rats and rhesus macaques [48] . Excretion in human breast milk has not been studied.
In terms of long-term follow up of infants, two retrospective case series examining the safety profile in HIV-infected pregnant women and their offspring reported no observed tenofovir-related toxicity in the children [49, 50] . More recently, preliminary data on perinatal tenofovir exposure did not find any evidence of renal impairment, abnormal bone metabolism or impaired growth in children exposed to tenofovir in utero [51] [52] [53] . However, studies in children taking tenofovir as treatment for HIV infection have reported decreased bone density, mostly reversible upon cessation [54, 55] .
Due to its growing safety data in pregnant women (albeit in HIV-infected rather than HBV-monoinfected pregnant women) and its potency and high barrier to resistance regarding HBV, it should be considered as a therapeutic option in women of reproductive age planning pregnancy or in pregnant women considering interventions to reduce perinatal HBV transmission.
Telbivudine
Telbivudine is an HBV-specific l-nucleoside analogue of thymidine. When activated by phosphorylation, it competes with naturally occurring thymidine triphosphate and is incorporated into the viral DNA leading to chain termination. Unlike other nucleoside analogues, such as lamivudine, telbivudine preferentially inhibits anti-complement or second-strand DNA [56] and has no activity towards other human viruses [57] .
Clinical studies comparing telbivudine with lamivudine demonstrated telbivudine to be superior to lamivudine in therapeutic response in HBeAg-positive patients [58, 59] . In HBeAg-positive patients telbivudine treatment was associated with higher rates of undetectable HBV DNA at 2 years, a higher proportion of patients had normalization of ALT at 2 years but there was no difference in HBeAg seroconversion compared with the group treated with lamivudine [58] . In HBeAg-negative patients, telbivudine was also associated with a higher rate of therapeutic response compared with lamivudine at 2 years [58] . Participants in this large trial were predominantly male with only approximately 25% of participants being female. In a recently reported study from China, 52 viraemic women were given telbivudine during the second or third trimesters of pregnancy, which resulted in a reduction of HBV DNA and HBeAg levels at delivery [60] . One-third of the telbivudine-treated mothers achieved an undetectable viral load prior to delivery. Infant follow-up at 7 months post-partum demonstrated a statistically significant difference in intrauterine transmission rate between the telbivudine and the control group (0% versus 18%; P<0.05) [60] . No serious adverse effects were noted in the telbivudinetreated mothers or their infants.
In pre-clinical animal studies telbivudine crossed the placenta in rats, but did not demonstrate any teratogenicity in rats or rabbits at doses 6× (rats) to 37× (rabbits) higher than therapeutic human doses [61] . An increase in premature delivery and abortion was observed in rabbits at plasma levels 37× higher than those in humans at therapeutic dose. Studies in male and female rats confirmed telbivudine had no effect on pregnancy rate or fertility and has shown no carcinogenic potential [61] . Data on human placental passage and breast milk excretion is not yet available.
Telbivudine has been taken by a small number of pregnant women and to date no congenital malformations have been reported to the Antiretroviral Pregnancy Registry for six first trimester exposures and eight second and third trimester exposure [27] .
Although the safety data of telbivudine looks promising and there is a small amount of experience in pregnant women infected with HBV, more clinical experience is required before its widespread use can be recommended.
Conclusions
Many women with chronic HBV who are being considered for treatment are of reproductive age; therefore, balancing their reproductive intent with their need for treatment to reduce progressive liver fibrosis is an important aspect of clinical management. Factors to consider include maternal age, extent of existing liver fibrosis, and safety and efficacy data of available licensed anti-HBV medications. Although none of these drugs are recommended in pregnancy, there is increasing safety and efficacy data (predominantly from the HIV-infected pregnant population) emerging particularly for lamivudine and tenofovir.
In addition, women who are on antivirals and become pregnant have one of three options. These include continuing therapy (particularly if this agent is lamivudine or tenofovir), ceasing therapy or switching to a drug with more safety data in pregnancy. The safety of ceasing therapy needs to be carefully considered as there is no data in the pregnancy setting detailing the clinical implications for the mother and/or the fetus of a hepatitis flare, particularly in the first trimester. In light of this, and in the scenario of women with significant liver fibrosis, switching to an agent such as lamivudine or tenofovir for the duration of the pregnancy may be warranted.
The third therapeutic scenario emerging is the role of antivirals for prevention of mother-to-child transmission of HBV. Only lamivudine has been demonstrated in a clinical trial to potentially confer benefit, although both tenofovir (due to its potency and safety data) along with telbivudine (due to its recent reported use in a small study of pregnant women) should also be considered, but warrant further study.
The implications of this include the following: for some women, treatment should not be delayed if it is clinically warranted, even if the woman is trying to conceive; and, there is a need to further investigate the additional benefit (if any) of anti-HBV medications other than lamivudine on preventing perinatal HBV transmission over and above the standard care of hepatitis B immunoglobulin and hepatitis B vaccination at birth.
With such a high burden of disease amongst women of reproductive age, and ongoing perinatal transmission occurring despite widespread use of hepatitis B immunoglobulin and hepatitis B vaccination at birth, further research of this population is warranted. There is an urgent need for more data in the pregnancy setting to guide our therapeutic choices. Moreover, while most of that focus has been on teratogenicity, there also needs to be a greater emphasis on efficacy of the various treatments in pregnancy and the evaluation of potential longterm effects of using these drugs in the third trimester of pregnancy and in the post-partum period.
